Receptor-Specific Delivery of Liposomes Via Folate-Peg-Chol

References

• Tardi P. G., Boman N. L., Cullis P. R. Liposomal Doxorubicin. J. Drug Targeting 1996; 4: 129–140
   PubMed Web of Science ®Google Scholar
• Leserman L. D., Weinstein J. N., Blumenthal R., Terry W. D. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc. Natl. Acad. Sci. USA 1980; 77: 4089–4093
   PubMed Web of Science ®Google Scholar
• Berinstein N., Matthay K. K., Papahadjopoulos D., Levy R., Sikie B. I. Antibody-directed targeting of liposomes to human cell lines: Role of binding and internalization on growth inhibition. Cancer Res. 1987; 47: 5954–5959
   PubMed Web of Science ®Google Scholar
• Allen T. M. Liposome targeting in animal models: problems and opportunities. J. Lipsome Res. 1997; 7: 315–329
   Web of Science ®Google Scholar
• Park J. W., Hong K., Kirpotin D. B., Meyer O., Papahadjopoulos D., Benz C. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Let 1997; 118: 153–160
   PubMed Web of Science ®Google Scholar
• Park J. W., Hong K., Kirpotin D. B., Papahadjopoulos D., Benz C. C. Immunoliposomes for cancer treatment. Adv. Pharmacol. 1997; 40: 399–435
   PubMedGoogle Scholar
• Garin-Chesa P., Campbell I., Saigo P., Lewis J., Old L., Rettig W. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immuno-pathology and molecular identification as a folate-binding protein. Am. J. Path. 1993; 142: 557–567
   PubMed Web of Science ®Google Scholar
• Ross J. F., Chaudhuri P. K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines-Physiologic and clinical applications. Cancer 1994; 73: 2432–2443
   PubMed Web of Science ®Google Scholar
• Weitman S. D., Lark R. H., Coney L. R., Fort D. W., Frasca V., Zurawski V. R. J., Kamen B. A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992; 52: 3396–3401
   PubMed Web of Science ®Google Scholar
• Crippa F., Buraggi G. L., Di Re E., Gasparini M. E., Seregni E., Canevari S., Gadina M., Presti M., Marini A., Seccamani E. Radioimmunoscintigra-phy of ovarian cancer with the MOvl8 monoclonal antibody. Eur. J. Cancer 1991; 27: 724–729
   PubMed Web of Science ®Google Scholar
• Crippa F., Bolis G., Seregni E., Gavoni N., Scarfone G., Ferraris C., Buraggi G. L., Bombardieri E. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1-131 MOvl8: clinical results in patients with minimal residual disease of ovarian cancer. Eur. J. Cancer 1995; 31A: 686–690
   PubMed Web of Science ®Google Scholar
• Paganelli G., Belloni C., Magnani P., Zito F., Pasini A., Sassi I., Merona M., Mariani M., Vignali M., Siccardi A. G., Fazio F. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur. J. Nucl. Med. 1992; 19: 322–329
   PubMedGoogle Scholar
• Coney L. R., Mezzanzanica D., Sanborn D., Casalini P., Colnaghi M. I., Zuraw-Ski V. R. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res. 1994; 54: 2448–2455
   PubMed Web of Science ®Google Scholar
• Canevari S., Stoter G., Arienti P., Bolis G., Colnaghi M. I., Di Re E., Eggermont M. M., Goey S. H., Gratama J. W., Lamers C. H. J., Nooy M. A., Parmiani G., Ras-Pagliesi F., Ravagnani F., Scarfone G., Trimbos J. B., Warnaar S. O., Bolhuis R. L.H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 1995; 87: 1463–1469
   PubMed Web of Science ®Google Scholar
• Leamon C. P., Low P. S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA 1991; 88: 5572–5576
   PubMed Web of Science ®Google Scholar
• Leamon C. P., Pastan I., Low P. S. Cytotoxicity of folate.-pseudomonas exotoxin conjugates toward tumor cells. J. Biol. Chem. 1993; 268: 24847–24854
   PubMed Web of Science ®Google Scholar
• Kranz D. M., Patrick T. A., Brigle K. E., Spinella M. J., Roy E. J. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. USA 1995; 92: 9057–9061
   PubMed Web of Science ®Google Scholar
• Lee R. J., Low P. S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 1994; 269: 3198–3204
   PubMed Web of Science ®Google Scholar
• Lee R. J., Low P. S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1995; 1233: 134–144
   PubMed Web of Science ®Google Scholar
• Gabizon A., Horowitz A. T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M. M., Zalipsky S. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconj. Chem. 1999; 10: 289–298
   PubMed Web of Science ®Google Scholar
• Guo W., Hinkle G. H., Lee R. J. 99mTc-HYNIC-folate, a novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. 1999; 40: 1563–1569
   PubMed Web of Science ®Google Scholar
• Li S., Deshmukh H. M., Huang L. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm. Res. 1998; 15: 1540–1545
   PubMed Web of Science ®Google Scholar
• Lee R. J., Huang L. Folate-targeted, anionic liposome entrapped, polyly-sine-condensed DNA (LPDII) for tumor cell-specific gene tranfer. J. Biol. Chem. 1996; 271: 8481–8487
   PubMed Web of Science ®Google Scholar
• Hwu P., Yang J. C., Cowherd Y. R., Treisman J., Shafer G. E., Eshhar Z., Rosenberg S. A. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995; 55: 3369–3373
   PubMed Web of Science ®Google Scholar
• Mayer L. D., Tai L. C. L., Ko D. S. C., Masin D., Ginsberg R. S., Cullis P. R., Bally M. B. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989; 49: 5922–5930
   PubMed Web of Science ®Google Scholar
• Bradley A. J., Devine D. V., Ansell S. M., Janzen J., Brooks D. E. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol-lipids. Arch, of Biochem. Biophys. 1998; 357: 185–94
   PubMed Web of Science ®Google Scholar
• Parr M. J., Ansell S. M., Choi L. S., Cullis P. R. Factors influencing the retention and chemical stability of poly(ethyleneglycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim. Biophys. Acta. 1994; 1195: 21–30
   PubMed Web of Science ®Google Scholar
• Chang S. S., O'Keefe D. S., Bacich D. J., Heston W. D. W., Reuter V. E., Gaudin P. B. Prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999; 59: 3192–3198
   PubMed Web of Science ®Google Scholar
• Shen F., Ross J. F., Wang X., Ratnam M. Identification of a novel folate receptor, a truncated receptor, and a receptor type p in hematopoietic cells: cloning, expression, immunoreactivity, and tissue specificity. Biochem. 1994; 33: 1209–1215
   PubMed Web of Science ®Google Scholar